Boehringer Ingelheim Signs $1.3 Billion Deal for Simcere’s Preclinical IBD Bispecific SIM0709
Boehringer Ingelheim entered a licensing and collaboration agreement with Shanghai-based Simcere Pharmaceutical Group on January 27, 2026, for global rights (excluding Greater China) to SIM0709, a preclinical bispecific antibody targeting TL1A and IL-23p19 for inflammatory bowel disease (IBD).
The deal includes an undisclosed upfront payment plus development, regulatory, and sales milestones totaling up to €1.05 billion ($1.26 billion), with royalties on net sales outside Greater China.
SIM0709 demonstrated superior synergistic efficacy in preclinical cell and animal studies compared to the combination of corresponding monotherapies.
The partnership aims to address unmet needs in IBD, where current therapies fail to prevent progression for many patients.
Boehringer has existing IBD assets like Cyltezo (Humira biosimilar) and a phase 2 TREM-1 antagonist for ulcerative colitis.